Gender characteristics of the pathogenesis, prevention and treatment of metabolic syndrome

Metabolic syndrome (MS) is widespread which explains high relevance of the topic. The MS development depends on various factors (age, race, social and economic status, level of physical activity, cultural development, diet, genetic background and educational level). Traditionally, the MS assessment and cardiovascular risk stratification includes measurement of total cholesterol, triglycerides, high density lipoprotein cholesterol, low density lipoprotein cholesterol, as well as glucose and insulin levels. Some other factors are being investigated and might serve as the surrogate endpoints for the effectiveness of treatment and prevention strategies in addition to insulin resistance indices (HOMA-IR, Caro). These include some systemic biomarkers such as highly sensitive C-reactive protein, leptin and adiponectin, which mediate the link between inflammation and obesity, as well as potentially prognostic markers of cardiovascular diseases. The paper considers the gender specificity of the MS and main components of the MS, such as hypertension, insulin resistance, obesity, and dyslipidemia. We review different approaches of international guidelines and specific regional and national characteristics and analyze gender-related peculiarities of each component of the MS in order to justify an individualized choice of management approach.

1. Grundy SM, Hansen B, Smith SC, Cleeman JI, Kahn RA. Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Arterioscler Thromb Vasc Biol. 2004;24(2):19-24. doi:10.n61/01.ATV.0000n2379.88385.67

2. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112(17):27352752. doi:10.1161/CIRCULATIONAHA.105.169404

3. Grundy SM. Metabolic syndrome pandemic. Arterioscler Thromb Vasc Biol. 2008;28(4):629-636. doi:10.1161/ATVBAHA.107.151092

4. Pucci G, Alcidi R, Tap L, Battista F, Mattace-Raso F, Schillaci G. Sexand gender-related prevalence, cardiovascular risk and therapeutic approach in metabolic syndrome: a review of the literature. Pharmacol Res. 2017;120:34-42. doi:10.1016/j.phrs.2017.03.008

5. Wenger NK. Women and coronary heart disease: a century after Herrick: understudied, underdiagnosed, and undertreated. Circulation. 2012;126(5):604-611.doi:10.1161/CIRCULATIONAHA.111.086892

6. Regitz-Zagrosek V, Oertelt-Prigione S, Prescott E, Franconi F, Gerdts E, Foryst-Ludwig A et al. Gender in cardiovascular diseases: impact on clinical manifestations, management, and outcomes. Eur Heart J. 2016;37(1):24-34. doi:10.1093/eurheartj/ehv598

7. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37(12):1595-1607.

8. Reaven GM. Role of insulin resistance in human disease (syndrome X): an expanded definition. Annu Rev Med. 1993;44(1):121-131. doi:10.1146/annurev.me.44.020193.00100

9. Lemieux I, Pascot A, Couillard C, Lamarche B, TchernofA, Almeras N et al. Hypertriglyceridemic waist: a marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men? Circulation. 2000;102(2): 179-184.

10. Kaplan NM. The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intern Med. 1989;149(7):1514-1520.

11. Grundy SM, Brewer HB, Cleeman JI, Smith SC, Lenfant C. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American HeartAssociation conference on scientific issues related to definition. Circulation. 2004;109(3):433438. doi:10.1161/01.CIR.0000111245.75752.C 6

12. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15(7):539-553.

13. Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med. 1999;16(5):442-443.

14. Third Report of the National Cholesterol Education Program. (NCEP) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation. 2002;106(25):3143-3421.

15. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome — a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med. 2006;23(5):469480. doi:10.1111/j.1464-5491.2006.01858.x

16. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120(16):1640-1645. doi:10.1161/CIRCULATIONAHA.109.192644

17. Regitz-Zagrosek V, Lehmkuhl E, Mahmoodzadeh S. Gender aspects of the role of the metabolic syndrome as a risk factor for cardiovascular disease. Gend Med. 2007;4(Suppl B): S 162-S 177. doi:10.1016/s1550-8579(07)80056-8

18. Harrrison RJ, Kannel WB, Stokes J, Castelli WP. Incidence and precursors of hypertension in young adults: the Framingham Offspring Study. Prev Med. 1987;16(2):235-251. doi:10.1016/00917435(87)90087-9

19. Moore JX, Chaudhary N, Akinyemiju T. Metabolic syndrome prevalence by race/ethnicity and sex in the United States, National Health and Nutrition Examination Survey, 1988-2012. Prev Chronic Dis. 2017;14: E 24. doi:10.5888/pcd14.160287

20. Aguilar M, Bhuket T, Torres S, Liu B, Wong RJ. Prevalence ofthe metabolic syndrome in the United States, 2003-2012. JAMA. 2015;313(19):1973-1974. doi:10.1001/jama.2015.4260

21. Regitz-Zagrosek V, Lehmkuhl E, Weickert MO. Gender differences in the metabolic syndrome and their role for cardiovascular disease. Clin Res Cardiol. 2006;95(3):136-147. doi:10.1007/s00392-006-0351-5

22. Wong RJ. Trends in prevalence of the metabolic syndromereply. J Am Med Assoc. 2015;314(9):950-951. doi:10.1001/jama.2015.8628

23. Lovre D, Mauvais-Jarvis F. Trends in prevalence of the metabolic syndrome—reply. J Am Med Assoc. 2015;314(9):950951. doi:10.1001/jama.2015.8625

24. Gupta R, Deedwania PC, Gupta A, Rastogi S, Panwar RB, Kothari K. Prevalence of metabolic syndrome in an Indian urban population. Int J Cardiol. 2004;97(2):257-261. doi:10.1016/j.ijcard.2003.11.003

25. Gu D, Reynolds K, Wu X, Chen J, Duan X, Reynolds RF et al. Prevalence of the metabolic syndrome and overweight among adults in China. Lancet. 2005;365(9468):1398-1405. doi:10.1016/S014-6736(05)66375-1

26. Cherry CO, Serieux E, Didier M, Nuttal ME, Schuster RJ. Prevalence of risk factors for the metabolic syndrome in the middle income Caribbean nation of st. Lucia. Adv Prev Med. 2014;2014:501972. doi:10.1155/2014/501972

27. Recommendations for the management of patients with metabolic syndrome: clinical guidelines. Ministry of Health of the Russian Federation. 2013. 42 р. [Electronic resource]. URL: https://cardioweb.ru/files/Klinicheskie_rekomendacii/Diagnostika_i_lechenie_metabolicheskogo_sindroma.docx (date of the access: 01.02.2020). In Russian.

28. Shavshin DA, Rotar OP, Solntsev VN, Konradi AO, Karpenko MA. The prevalence of metabolic syndrome in a sample of residents of Kaliningrad. Arterial’naya Gipertenziya = Arterial Hypertension. 2015;21(6):630-638. In Russian.

29. Rotar OP, Libis RA, Isaeva EN, Erina AM, Shavshin DA, Moguchaya EV et al. Metabolic syndrome prevalence in Russian cities. Russ J Cardiology. 2012;2(94):55-62. In Russian.

30. Vishram JK, Borglykke A,AndreasenAH, Jeppesen J, Ibsen H, Jorgensen T et al. Impact of age and gender on the prevalence and prognostic importance of the metabolic syndrome and its components in Europeans. The MORGAM Prospective Cohort Project. PLoS One. 2014;9(9):e107294. doi:10.1371/journal.pone.0107294

31. Park E, Kim J. Genderand age-specific prevalence of metabolic syndrome among Korean adults: analysis of the fifth Korean National Health and Nutrition Examination Survey. J Cardiovasc Nurs. 2015;30(3):256-266. doi:10.1097/JCN.0000000000000142

32. Moreira GC, Cipullo JP, Ciorlia LA, Cesarino CB, VilelaMartin JF. Prevalence of metabolic syndrome: association with risk factors and cardiovascular complications in an urban population. PLoS One. 2014;9(9):105056. doi:10.1371/journal.pone.0105056

33. Santos AC, Ebrahim S, Barros H. Gender, socio-economic status and metabolic syndrome in middle-aged and old adults. BMC Public Health. 2008;8:62. doi:10.1186/1471-2458-8-62

34. Karamnova NS, Maksimov SA, Shalnova SA, Balanova YuA, Imaeva AE, Muromtseva GA et al. Educational and nutritional status of the adult population of the Russian Federation. The results of an epidemiological study ESSE-RF. Cardiovascular Therapy and Prevention. 2019;18(5):80-89. In Russian.

35. Zhernakova YuV, Zheleznova EA, Chazova IE, Oshchepkova EV, Dolgusheva YuA, Yarovaya EB et al. The prevalence of abdominal obesity and the association with socioeconomic status in Regions of the Russian Federation: the results of the epidemiological study ESSE-RF. Ter Arkh. 2018;90(10):14-22. In Russian.

36. Kreiger N, KoshelevaA, Waterman PD, Chen JT, Beckfield J, Kiang MV. 50-year trends in US socioeconomic inequalities in gealth: US-born Black and White Americans, 1959-2008. Intern J Epidemiol. 2014;43(4):1294-1313. doi:10.1093/ije/dyu047

37. Toms R, Bonney A, Mayne DJ, Feng X, Walsan R. Geographic and area-level socioeconomic variation in cardiometabolic risk factor distribution: a systematic review of the literature. Int J Health Geogr. 2019;18(1):1. doi:10.1186/s12942-018-0165-5

38. Chazova IE, Zhernakova YuV on behalf of the experts. Clinical guidelines. Diagnosis and treatment of arterial hypertension. Systemic Hypertension. 2019;16(1):6-31. In Russian.

39. Egan B, Kjeldsen S, Grasi G, Esler M, Mancia G. The global burden of hypertension exceeds 1.4 billion people: should a systolic blood pressure target below 130 become the universal standard? J Hypertension. 2019;37(6):1148-1153. doi:10.1097/hjh.0000000000002021

40. Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R et al. Heart disease and stroke statistics — 2017 update: a report from the American Heart Association. Circulation. 2017;135(10):146-603. doi:10.1161/CIR.0000000000000485

41. Ong KL, Tso AW, Lam KS, Cheung BM. Gender difference in blood pressure control and cardiovascular risk factors in Americans with diagnosed hypertension. Hypertension. 2008;51(4):1142-1148. doi:10.1161HYPERTENSIONAHA.107.105205

42. Shaposhnik II, Sinitsyn SP, Bubnova VS, Chulkov VS. Arterial hypertension in young adults. M.: Medpractika-M, 2011. 140 p. In Russian.

43. Wang L, Wang X, Qu HY, Jiang S, Zhang J, Fu L et al. Role of kidneys in sex differences in angiotensin II-induced hypertension. Hypertension. 2017;70(6):1219-1227. doi:10.1161/HYPERTENSIONAHA.117.10052

44. Zhang Z, Wang W, Jin H, Chen X, Cheng Y, Xu Y et al. Apelin is a negative regulator of angiotensin II-mediated adverse myocardial remodeling and dysfunction. Hypertension. 2017;70(6): 1165-1175. doi:10.1161/HYPERTENSIONAHA.117.10156

45. Song JJ, Ma Z, Wang J, Chen LX, Zhong JC. Gender differences in hypertension. J Cardiovasc Transl Res. 2020;13(1): 47-54. doi:10.1007/s12265-019-09888-z

46. Reckelhoff JF. Sex Differences in regulation of blood pressure. Sex-specific analysis of cardiovascular function. Adv Exp Med Biol. 2018;1065:139-151. doi:10.1007/978-3-319-77 932-4_9

47. O’Donnell E, Floras JS, Harvey PJ. Estrogen status and the renin angiotensin aldosterone system. Am J Physiol Regul Integr Comp Physiol. 2014;307(5):498-500. doi:10.1152/ajpregu.00182.2014

48. Moretti C, Lanzolla G, Moretti M, Gnessi L, Caimina E. Androgens and hypertension in men and women: a unifying view. Curr Hypertens Rep. 2017;19(5):44. doi:10.1007/s11906-0170740-3

49. DuPont JJ, Kenney RM, Patel AR, Jaffe IZ. Sex differences in mechanisms of arterial stiffness. Br J Pharmacol. 2019;176(21):4208-4225. doi:10.1111/bph.14624

50. Corrigan FE, Al Mheid I, Eapen DJ, Hayek SS, Sher S, Martin GS et al. Low testosterone in men predicts impaired arterial elasticity and microvascular function. Int J Cardiol. 2015;194:9499. doi:10.1016/j.ijcard.2015.05.065

51. Maas AH, Appelman YE. Gender differences in coronary heart disease. Neth Heart J. 2010;18(12):598-602. doi:10.1007/s12471-010-0841-y

52. Wexler DJ, Grant RW, Meigs JB, Nathan DM, Cagliero E. Sex disparities in treatment of cardiac risk factors in patients with type 2 diabetes. Diabetes Care. 2005;28(3):514-520. doi:10.2337/diacare.28.3.514

53. Kautzky-Willer A, Harreiter J, Pacini G. Sex and gender differences in risk, pathophysiology and complications of type 2 diabetes mellitus. Endocr Rev. 2016;37(3):278-316. doi:10.1210/er.2015-1137

54. Geer EB, Shen W. Gender differences in insulin resistance, body composition, and energy balance. Gend Med. 2009;6(Suppl1):60-75. doi:10.1016/j.genm.2009.02.002

55. Varlamov O, Bethea CL, Roberts CT. Sex-specific differences in lipid and glucose metabolism. Front Endocrinol (Lausanne). 2015;5:241. doi:10.3389/fendo.2014.00241

56. Salas-Salvado J, Granada M, Bullo M, Corominas A, Casas P, Foz M. Plasma adiponectin distribution in a Mediterranean population and its association with cardiovascular risk factors and metabolic syndrome. Metabolism. 2007;56(11):1486-1492. doi:10.1016/j.metabol.2007.06.014

57. Lopez-Jaramillo P. The role of adiponectin in cardiometabolic diseases: effects of nutritional interventions. J Nutr. 2016;146(2): 422-426. doi:10.3945/jn.114.202432

58. Ding EL, Song Y, Malik VS, Liu S. Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA. 2006;295(11):1288-1299. doi:10.1001/jama.295.11.1288

59. Palmisano BT, Zhu L, Eckel RH, Stafford JM. Sex differences in lipid and lipoprotein metabolism. Mol Metab. 2018;15:45-55. doi:10.1016/j.molmet.2018.05.008

60. Wang X, Magkos F, Mittendorfer B. Sex differences in lipid and lipoprotein metabolism: it’s not just about sex hormones. J Clin Endocrinol Metab. 2011;96(4):885-893. doi:10.1210/jc.2010-2061

61. Paredes S, Fonseca L, Ribeiro L, Ramos H, Oliveira JC, Palma I. Novel and traditional lipid profiles in metabolic syndrome reveal a high atherogenicity. Sci Rep. 2019;9(1):11792. doi:10.1038/s41598-019-48120-5

62. Magkos F, Mittendorfer B. Gender differences in lipid metabolism and the effect of obesity. Obstet Gynecol Clin North Am. 2009;36(2):245-265. doi:10.1016/j.ogc.2009.03.001

63. Freedman DS, Otvos JD, Jeyarajah EJ, Shalaurova I, Cupples LA, Parise H et al. Sex and age differences in lipoprotein subclasses measured by nuclear magnetic resonance spectroscopy: the Framingham Study. Clin Chem. 2004;50(7):1189-1200. doi:10.1373/clinchem.2004.032763

64. Mora S, Szklo M, Otvos JD, Greenland P, Psaty BM, Goff DC et al. LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis. 2007;192(1):211-217. doi:10.1016/j.atherosclerosis.2006.05.007

65. Аметов А. С. Ожирение. Современный взгляд на патогенез и терапию: учебное пособие. М.: Гэотар-Медиа, 2019. Т. 1. 384 с. [Ametov AS. Obesity. A modern view of pathogenesis and therapy: a training manual. M.: Geotar-Media, 2019. Vol. 1. 384 p. In Russian].

66. Ng M, Fleming T, Robinson M, Thomson B, Graetz N, Margono C et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2014;384(9945):766-781. doi:10.1016/S01406736(14)60460-8

67. Abarca-Gomez L, Abdeen ZA, Hamid ZA. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in bodymass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128 9 million children, adolescents, and adults. Lancet. 2017;390(10113):2627-2642. doi:10.1016/s0140-6736(17)32129-3

68. Dedov II, Mel’nichenko GA, Shestakova MV, Vikulova OK, Galstyan GR, Kuraeva TL et al. Russian national clinical recommendations for morbid obesity treatment in adults. 3rd revision (Morbid obesity treatment in adults). Obes Metab. 2018;15(1):53-70. doi:10.14341/OMET2018153-70. In Russian.

69. Whitlock G, Lewington S, Sherliker P, Clarke R, Emberson J, Halsey J et al. Body-mass index and causespecific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet. 2009;373(9669):1083-1096. doi:10.1016/S0140-6736(09) 60318-4

70. Janiiszewski PM, Janssen I, Ross R. Does waist circum-ference predict diabetes and cardiovascular disease beyond commonly evaluated cardio metabolic risk factors? Diabetes Care. 2007;30(12):3105-3109. doi:10.2337/dc07-0945

71. Korhonen PE, Jaatinen PT, Aarnio PT, Kantola IM, Saaresranta T: Waist circumference home measurement—a device to find out patients in cardiovascular risk. Eur J Public Health. 2009;19(1):95-99. doi:10.1093/eurpub/ckn090

72. MisraA, Wasir JS, Vikram NK. Waist circumference criteria for the diagnosis of abdominal obesity are not applicable uniformly to all populations and ethnic groups. Nutrition. 2005;21(9):969-976. doi:10.1016/j.nut.2005.01.007

73. Peer N, Lombard C, Steyn K, Levitt N. Utility of waist-toheight ratio as an Indicator of cardio-metabolic risk compared with routinely used adiposity indices. J Hypertens. 2018;36(Suppl 1): e85. doi:10.1097/01.hjh.0000539210.78354.b9

74. Ashwell M, Gunn P, Gibson S. Waist-to-height ratio is a better screening tool than waist circumference and BMI for adult cardiometabolic risk factors: systematic review and metaanalysis. Obes Rev. 2012;13(3):275-286. doi:10.1111/j.1467789X.2011.00952.x

75. Kanter R, Caballero B. Global gender disparities in obesity: a review. Adv Nutr. 2012;3(4):491-498. doi:10.3945/an.112.002063

76. Oza-Frank R, Cunningham SA. The weight of US residence among immigrants: a systematic review. Obes Rev. 2010;11(4):271280. doi:10.1111/j.1467-789X.2009.00610.x

77. Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol. 2010;56(14):11131132. doi:10.1016/j.jacc.2010.05.034

78. Wu SH, Liu Z, Ho SC. Metabolic syndrome and all-cause mortality: a meta-analysis of prospective cohort studies. Eur J Epidemiol. 2010;25(6):375-384. doi:10.1007/s10654-010-9459-z

79. Galassi A, Reynolds K, He J. Metabolic syndrome and risk of cardiovascular disease: a metaanalysis. Am J Med. 2006;119(10):812-819. doi:10.1016/j.amjmed.2006.02.031

80. Guzder RN, Gatling W, Mullee MA, Byme CD. Impact of metabolic syndrome criteria on cardiovascular disease risk in people with newly diagnosed type 2 diabetes. Diabetologia. 2006;49(1):4955. doi:10.1007/s00125-005-0063-9

81. Guize L, Thomas F, Pannier B, Bean K, Jego B, Benetos A. All-cause mortality associated with specific combinations of the metabolic syndrome according to recent definitions. Diabetes Care. 2007;30(9):2381-2387. doi:10.2337/dc07-0186

82. Peters SA, Huxley RR, Woodward M. Diabetes as a risk factor for stroke in women compared with men: a systematic review and meta-analysis of 64 cohorts, including 775,385 individuals and 12,539 strokes. Lancet. 2014;383(9933): 1973—1980. doi:10.1016/S0140-6736(14)60040-

83. Kuk JL, Ardern CI. Age and sex differences in the clustering of metabolic syndrome factors: association with mortality risk. Diabetes Care. 2010;33(11):2457-2461. doi:10.2337/dc10-0942

84. Ferrara A, Mangione CM, Kim C, Marrero DG, Curb D, Stevens M et al. Sex disparities in control and treatment of modifiable cardiovascular disease risk factors among patients with diabetes: Translating Research Into Action for Diabetes (TRIAD) Study. Diabetes Care. 2008;31(1):69-74. doi:10.2337/dc07-1244

85. Gouni-Berthold I, Berthold HK, Mantzoros CS, Bohm M, Krone W. Sex disparities in the treatment and control of cardiovascular risk factors in type 2 diabetes. Diabetes Care. 2008;31(7):13891391. doi:10.2337/dc08-0194

86. Aspry KE, Van Horn L, Carson JAS, Wylie-Rosett J, Kushner RF, Lichtenstein AH et al. Medical nutrition education, training, and competencies to advance guideline-based diet counseling by physicians: A Science Advisory from the American Heart Association. Circulation. 2018;137(23):e821-e841. doi:10. 1161/CIR.0000000000000563

87. Aguilar-Salinas CA, Viveros-Ruiz T. Recent advances in managing/understanding the metabolic syndrome. F1000Res. 2019;8:370. doi:10.12688/f1000research.17122.1.88

88. Orchard TJ, Temprosa M, Goldberg R, Haffner S, Ratner R, Marcovina S et al. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med. 2005;142(8):611-619. doi:10.7326/0003-4819-142-8-200504190-00009

89. Vissers D, Hens W, Taeymans J, Baeyens JP, Poortmans J, Van Gaal L. The effect of exercise on visceral adipose tissue in overweight adults: a systematic review and meta-analysis. PLoS One. 2013;8(2):e56415. doi:10.1371/journal.pone.0056415

90. Rochlani Y, Pothineni NV, Kovelamudi S, Mehta JL. Metabolic syndrome: pathophysiology, management, and modulation by natural compounds. Ther Adv Cardiovasc Dis. 2017;11(8):215225. doi:10.1177/1753944717711379